Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Kefford

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Archives of Internal Medicine|January 25, 2006
Association between circulating white blood cell count and cancer mortality: a population-based cohort studyAnoop Shankar, Jie Jin Wang, Elena Rochtchina, et al.
Internal Medicine Journal|November 2, 2020
Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancyAbhishikta Dey, Nicholas Manolios, Georgina V Long, et al.
The Australasian Journal of Dermatology|December 10, 2013
Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinibRachael Anforth, Michael Liu, Bao Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapyKatarzyna D Chmiel, Dan Suan, Christopher Liddle, et al.
Internal Medicine Journal|May 10, 2017
Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in AustraliaYeh Chen Lee, René Kroon, Bogda Koczwara, et al.
BMJ Open|March 25, 2020
Clinicians' attitudes to oncology clinical practice guidelines and the barriers and facilitators to adherence: a mixed methods study protocolMia Bierbaum, Jeffrey Braithwaite, Gaston Arnolda, et al.
Journal of Translational Medicine|August 16, 2013
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophiliaAndreas Carus, Howard Gurney, Val Gebski, et al.
Journal of the American Academy of Dermatology|January 23, 2016
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortShelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
Journal of the American Academy of Dermatology|March 10, 2015
Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapyRachael Anforth, Alexander Menzies, Karen Byth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanomaKeith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Archives of Internal Medicine|January 25, 2006
Association between circulating white blood cell count and cancer mortality: a population-based cohort studyAnoop Shankar, Jie Jin Wang, Elena Rochtchina, et al.
Internal Medicine Journal|November 2, 2020
Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancyAbhishikta Dey, Nicholas Manolios, Georgina V Long, et al.
The Australasian Journal of Dermatology|December 10, 2013
Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinibRachael Anforth, Michael Liu, Bao Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapyKatarzyna D Chmiel, Dan Suan, Christopher Liddle, et al.
Internal Medicine Journal|May 10, 2017
Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in AustraliaYeh Chen Lee, René Kroon, Bogda Koczwara, et al.
BMJ Open|March 25, 2020
Clinicians' attitudes to oncology clinical practice guidelines and the barriers and facilitators to adherence: a mixed methods study protocolMia Bierbaum, Jeffrey Braithwaite, Gaston Arnolda, et al.
Journal of Translational Medicine|August 16, 2013
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophiliaAndreas Carus, Howard Gurney, Val Gebski, et al.
Journal of the American Academy of Dermatology|January 23, 2016
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortShelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
Journal of the American Academy of Dermatology|March 10, 2015
Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapyRachael Anforth, Alexander Menzies, Karen Byth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanomaKeith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Pageof 7